Literature DB >> 18461298

[Radiological diagnostics of malignant tumors of the musculoskeletal system in childhood and adolescence].

S F Nemec1, C R Krestan, A Hojreh, M Hörmann.   

Abstract

Rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma are the most common malignant tumors of the musculoskeletal system in childhood and adolescence representing about 10% of newly diagnosed cancers in children and adolescents.In the last two decades the prognosis of patients with such malignancies improved significantly. On the one hand because of the advances in chemotherapy and orthopedic surgery, on the other hand also because of the innovations in radiological diagnostics. The precise pre-therapeutical staging of tumors of the musculoskeletal system provides important prognostic information and has impact on the entire therapy management. During respectively after therapy, imaging is extremely important in the follow-up and in diagnosing a possible recurrent disease.Modern imaging diagnostics of musculoskeletal tumors basically consist of conventional X-ray, of computed tomography (CT) and magnetic resonance imaging (MRI), and of modalities of nuclear medicine such as szintigraphy, positron emission tomography (PET) and PET CT.

Entities:  

Mesh:

Year:  2008        PMID: 18461298     DOI: 10.1007/s00117-008-1651-8

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  28 in total

1.  [Radiological diagnosis of bone tumors. 2].

Authors:  R Erlemann
Journal:  Radiologe       Date:  2001-11       Impact factor: 0.635

Review 2.  Rhabdomyosarcoma in pediatric patients: the good, the bad, and the unusual.

Authors:  M B McCarville; S L Spunt; A S Pappo
Journal:  AJR Am J Roentgenol       Date:  2001-06       Impact factor: 3.959

Review 3.  Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.

Authors:  D M Parham
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

4.  Magnetic resonance imaging-guided percutaneous biopsy of musculoskeletal lesions.

Authors:  John A Carrino; Bharti Khurana; John E Ready; Stuart G Silverman; Carl S Winalski
Journal:  J Bone Joint Surg Am       Date:  2007-10       Impact factor: 5.284

Review 5.  [Standards and diagnostic strategies in diagnosis of bone tumors and tumor-simulating lesions].

Authors:  J Freyschmidt
Journal:  Radiologe       Date:  1998-04       Impact factor: 0.635

6.  CT halo sign in metastasis of osteosarcoma.

Authors:  N Tomiyama; J Ikezoe; M Miyamoto; K Nakahara
Journal:  AJR Am J Roentgenol       Date:  1994-02       Impact factor: 3.959

7.  CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group.

Authors:  D M Panicek; C Gatsonis; D I Rosenthal; L L Seeger; A G Huvos; S G Moore; D J Caudry; W E Palmer; B J McNeil
Journal:  Radiology       Date:  1997-01       Impact factor: 11.105

8.  [The staging of malignant bone tumors].

Authors:  J Freyschmidt; J Wiers
Journal:  Radiologe       Date:  1998-06       Impact factor: 0.635

Review 9.  Soft-tissue tumors update: MR imaging features according to the WHO classification.

Authors:  Joan C Vilanova; Klaus Woertler; José A Narváez; Joaquim Barceló; Salutario J Martínez; Miguel Villalón; Josefina Miró
Journal:  Eur Radiol       Date:  2006-02-18       Impact factor: 5.315

10.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.

Authors:  Thomas Völker; Timm Denecke; Ingo Steffen; Daniel Misch; Stefan Schönberger; Michail Plotkin; Juri Ruf; Christian Furth; Brigitte Stöver; Hubertus Hautzel; Günter Henze; Holger Amthauer
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

View more
  1 in total

1.  Laryngeal embryonal rhabdomyosarcoma in an adult - a case presentation in the eyes of geneticists and clinicians.

Authors:  Wojciech Kukwa; Piotr Wojtowicz; Beata Jagielska; Grzegorz Sobczyk; Andrzej Kukwa; Anna M Czarnecka
Journal:  BMC Cancer       Date:  2011-05-12       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.